As the country emerges from the COVID-19 pandemic, it’s time to evaluate and assess lessons learned and find any possible silver linings derived from the crisis. This includes telehealth and the use of remote technology.
COVID-19 ushered in a fundamental change in how medicine is being delivered.
Analysts expect 2020 to be a busy year for M&A activity.
A discussion of the changing medtech markets and how companies can remain cognizant of potentially disruptive changes in their business and industry for future success in their product portfolios, services and relationships.
Medtech companies must account for a more complex web of influencers on purchasing.
Peter Micca of Deloitte discusses the changes that are happening within the healthcare ecosystem as a whole.
The adoption of accurate non-invasive measures of liver health at the point of care is critical.
Medical device companies will be driven to evolve their business models to a more patient/consumer-centric approach.
Technology isn’t the only driver in this change; the sociological factor plays a role as well.
As the Internet of Things and the reimbursement environment transform the healthcare ecosystem, device manufacturers must position themselves to adapt.